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Listening to fluoxetine: a hot message from the FLAME
trial of poststroke motor recovery
Steven C. Cramer
The fluoxetine for motor recovery after acute ischemic stroke
study was a double blind, placebo-controlled trial examining
the effects of fluoxetine in patients five- to 10 days after an
ischemic stroke. The study found motor improvement to 90
days poststroke, measured as the change in the Fugl–Meyer
score, was significantly greater in the fluoxetine group as
compared with the placebo group, and that this finding was
significant after adjusting for depression. Patients rando-
mized to fluoxetine also had less disability (modified Rankin
Scale 0–2). The study adds to the weight of data suggesting
that viable strategies exist to improve patient outcomes by
initiating a restorative agent, days after stroke injury is fixed.
Stroke remains among the leading causes of humandisability.
Currently, aminority of patients can access approved reperfu-
sion therapies, and among those so treated a substantial
fraction derives limited benefit. Therapies that target restora-
tive events have a timewindowmeasured in days–weeks and
so hold the potential to help many patients with stroke.
Key words: clinical trial, plasticity, recovery, selective seroto-
nin reuptake inhibitors, stroke
Numerous approaches are being pursued for promoting brain
repair after stroke (1). Growth factors, monoclonal antibodies,
cells, electromagnetic brain stimulation, lasers, robotic de-
vices, intensive physiotherapy regimens, and small molecules
have each been examined, and are at various stages of devel-
opment. The category of small molecules is particularly broad
and includes modulation of brain neurotransmitters.
Although much of the focus on neurotransmitters to date
has been on drugs affecting catecholamines, recent studies also
support therapies targeting serotonin.
Serotonin is a monoamine neurotransmitter that is central
to numerous brain functions, particularly affect and cognition,
and can influence motor cortex activity. Early studies examin-
ing selective serotonin reuptake inhibitor (SSRI) effects on
poststroke outcomes were favorable, for example, Miyai and
Reding (2) found that the reduction in disability provided by
fluoxetine for patients in the early weeks after stroke was
significantly better than that provided by the noradrenergic
drug desipramine or placebo; comparable results were found
by Dam et al. (3). Pariente et al. (4), using functional magnetic
resonance imaging in eight subjects two-weeks after a lacunar
stroke, found that a single dose of fluoxetine increased ipsile-
sional motor cortex activity in association with improved
function of the affected hand. Recent, larger trials have
strengthened the case for SSRI drugs in stroke recovery (5,
6), for example, Jorge et al. (6) found that, among 129 patients
randomized within three-months of stroke, cognitive out-
comes at 12-month poststroke were significantly better among
those randomized to the SSRI escitalopram, as compared with
problem-solving therapy or placebo. Importantly, these effects
were independent of any depression.
It is with this crescendo of SSRImomentum that Chollet et al.
(7)published the fluoxetine for motor recovery after acute
ischemic stroke (FLAME) study. This was a double-blind,
placebo-controlled trial that enrolled patients from nine stroke
centers in France. Entry criteria included ischemic stroke five- to
10 days old, moderate–severe weakness, age 18–85, NIHSS score
r20, and no depression. Patients were randomized to 20mg
fluoxetine or placebo, orally, once daily, for three-months.
The patients began therapy, at an average of nine-days after a
stroke, which was on an average of moderate severity (baseline
NIHSS5 13) but with severe weakness. Strokes were predo-
minantly supratentorial nonlacunar infarcts. The rate of IV
thrombolysis was high (32%). The primary outcome measure
was the change between enrollment and day 90 in the Fugl–
Meyer Motor Scale, an assessment of arm and leg motor
function with scores ranging from 0 (worst) to 100 (normal).
The two groups were well balanced at baseline, though a slight
imbalance in motor status favored the fluoxetine group. All
enrollees underwent standard physiotherapy concomitant
with study medication.
The main finding of the study was that the change in Fugl–
Meyer score in the fluoxetine group was significantly greater
than in the placebo group (34 vs. 24 points, P5 0.003). This
gain remained significant after adjustment for depressionDOI: 10.1111/j.1747-4949.2011.00618.x
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diagnosis, and was apparent in both affected arm and leg.
Regarding global outcome measures, responder analysis
showed a significant effect for the modified Rankin Scale (%
patients with 0–2) but not for the NIHSS (% patients with
0–5). Depression was four times more common among
patients in the placebo group.
The FLAME study is small by some standards and so
independent replication will be welcomed. Remarkably, pri-
mary analysis included some patients in the placebo arm who
developed depression and were switched to open label fluox-
etine. This indicates that the true difference between fluoxetine
and placebo might be greater than current results suggested.
The FLAME study raise issues central to restorative stroke
trials (8). First, the results lend support to modality-specific
endpoints in restorative stroke trials. The Fugl–Meyer score
demonstrated a significant difference in motor gains between
the two treatment arms, whereas only some of the global
endpoints did. In a restorative trial setting, some neurological
domains such as motor or language might improve while
others, such as those whose anatomical underpinnings are
decimated by stroke, might not. Restorative trials might
therefore include modality-specific endpoints to best capture
treatment effects, and also include appropriate measures of
activity and participation to best interpret these effects (9).
Second, stroke recovery occurs on the backbone of neural
plasticity events that are experience-dependent (10). Phy-
siotherapy, speech therapy, and other experiences provided
in parallel to restorative drug exposure are thus part of the
equation. Further studies are needed in this area, for example,
to understand how specific dimensions of concomitant ex-
perience influence drug effects, or how to best capture the
extent of these therapies.
Exciting results generate many questions. How will the
FLAME results extend to stroke populations with a broader
range of baseline deficits?What is the therapeutic timewindow
for initiating therapy, e.g. can we help patients with fixed
deficits five-years poststroke? Do the findings persist at one-
year poststroke? In this regard, do the gains provided by 90
days of fluoxetine stay or go if the drug is discontinued? Can
those patients most likely to respond to this restorative agent
be prospectively identified?
Some clinicians will interpret the FLAME study results as
establishing utility of fluoxetine for many patients with motor
deficits after stroke, while others will await clarification and
replication. Regardless, the FLAME study adds to the weight of
data suggesting that viable strategies exist to improve patient
outcomes by initiating a restorative agent days after stroke
injury is fixed. Chollet et al. (7) are to be congratulated for a
study that is likely to have amajor impact on treating stroke for
years to come.
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